152 related articles for article (PubMed ID: 30387762)
1. A structure-guided approach to ameliorate sickle cell disease.
Richter-Addo GB
Acta Crystallogr D Struct Biol; 2018 Nov; 74(Pt 11):1039-1040. PubMed ID: 30387762
[No Abstract] [Full Text] [Related]
2. Rational design of pyridyl derivatives of vanillin for the treatment of sickle cell disease.
Pagare PP; Ghatge MS; Musayev FN; Deshpande TM; Chen Q; Braxton C; Kim S; Venitz J; Zhang Y; Abdulmalik O; Safo MK
Bioorg Med Chem; 2018 May; 26(9):2530-2538. PubMed ID: 29655608
[TBL] [Abstract][Full Text] [Related]
3. Rational modification of vanillin derivatives to stereospecifically destabilize sickle hemoglobin polymer formation.
Deshpande TM; Pagare PP; Ghatge MS; Chen Q; Musayev FN; Venitz J; Zhang Y; Abdulmalik O; Safo MK
Acta Crystallogr D Struct Biol; 2018 Oct; 74(Pt 10):956-964. PubMed ID: 30289405
[TBL] [Abstract][Full Text] [Related]
4. Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin.
Abdulmalik O; Ghatge MS; Musayev FN; Parikh A; Chen Q; Yang J; Nnamani I; Danso-Danquah R; Eseonu DN; Asakura T; Abraham DJ; Venitz J; Safo MK
Acta Crystallogr D Biol Crystallogr; 2011 Nov; 67(Pt 11):920-8. PubMed ID: 22101818
[TBL] [Abstract][Full Text] [Related]
5. Voxelotor (GBT440) produces interference in measurements of hemoglobin S.
Rutherford NJ; Thoren KL; Shajani-Yi Z; Colby JM
Clin Chim Acta; 2018 Jul; 482():57-59. PubMed ID: 29601794
[No Abstract] [Full Text] [Related]
6. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
Henry ER; Metaferia B; Li Q; Harper J; Best RB; Glass KE; Cellmer T; Dunkelberger EB; Conrey A; Thein SL; Bunn HF; Eaton WA
Blood; 2021 Sep; 138(13):1172-1181. PubMed ID: 34197597
[TBL] [Abstract][Full Text] [Related]
7. Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia.
Strader MB; Liang H; Meng F; Harper J; Ostrowski DA; Henry ER; Shet AS; Eaton WA; Thein SL; Alayash AI
Bioconjug Chem; 2019 Mar; 30(3):568-571. PubMed ID: 30794381
[TBL] [Abstract][Full Text] [Related]
8. Biological activity of liposomal vanillin.
Castan L; Del Toro G; Fernández AA; González M; Ortíz E; Lobo D
J Med Food; 2013 Jun; 16(6):551-7. PubMed ID: 23767864
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease.
Xu GG; Pagare PP; Ghatge MS; Safo RP; Gazi A; Chen Q; David T; Alabbas AB; Musayev FN; Venitz J; Zhang Y; Safo MK; Abdulmalik O
Mol Pharm; 2017 Oct; 14(10):3499-3511. PubMed ID: 28858508
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for the potent antisickling effect of a novel class of five-membered heterocyclic aldehydic compounds.
Safo MK; Abdulmalik O; Danso-Danquah R; Burnett JC; Nokuri S; Joshi GS; Musayev FN; Asakura T; Abraham DJ
J Med Chem; 2004 Sep; 47(19):4665-76. PubMed ID: 15341482
[TBL] [Abstract][Full Text] [Related]
11. Vanillin, a potential agent for the treatment of sickle cell anemia.
Abraham DJ; Mehanna AS; Wireko FC; Whitney J; Thomas RP; Orringer EP
Blood; 1991 Mar; 77(6):1334-41. PubMed ID: 2001455
[TBL] [Abstract][Full Text] [Related]
12. Pyridyl derivatives of benzaldehyde as potential antisickling agents.
Nnamani IN; Joshi GS; Danso-Danquah R; Abdulmalik O; Asakura T; Abraham DJ; Safo MK
Chem Biodivers; 2008 Sep; 5(9):1762-9. PubMed ID: 18816529
[TBL] [Abstract][Full Text] [Related]
13. 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells.
Abdulmalik O; Safo MK; Chen Q; Yang J; Brugnara C; Ohene-Frempong K; Abraham DJ; Asakura T
Br J Haematol; 2005 Feb; 128(4):552-61. PubMed ID: 15686467
[TBL] [Abstract][Full Text] [Related]
14. O2 dependence of K+ transport in sickle cells: the effect of different cell populations and the substituted benzaldehyde 12C79.
Gibson JS; Khan A; Speake PF; Ellory JC
FASEB J; 2001 Mar; 15(3):823-32. PubMed ID: 11259401
[TBL] [Abstract][Full Text] [Related]
15. Sickle hemoglobin oxygen affinity-shifting strategies have unequal cerebrovascular risks.
Hebbel RP; Hedlund BE
Am J Hematol; 2018 Mar; 93(3):321-325. PubMed ID: 29150874
[No Abstract] [Full Text] [Related]
16. The molecular basis of antisickling agents.
Franklin IM; Huehns ER
Trans R Soc Trop Med Hyg; 1980; 74(6):695-700. PubMed ID: 7210123
[No Abstract] [Full Text] [Related]
17. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
Oksenberg D; Dufu K; Patel MP; Chuang C; Li Z; Xu Q; Silva-Garcia A; Zhou C; Hutchaleelaha A; Patskovska L; Patskovsky Y; Almo SC; Sinha U; Metcalf BW; Archer DR
Br J Haematol; 2016 Oct; 175(1):141-53. PubMed ID: 27378309
[TBL] [Abstract][Full Text] [Related]
18. Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (third of three parts).
Dean J; Schechter AN
N Engl J Med; 1978 Oct; 299(16):863-70. PubMed ID: 692579
[No Abstract] [Full Text] [Related]
19. Extracorporeal treatment of erythrocytes in sickle cell anemia: hemoglobin carbamylation.
Diederich D; Curran M; Odenbaugh A; Diederich A; Core E
Tex Rep Biol Med; 1980-1981; 40():313-22. PubMed ID: 7323976
[No Abstract] [Full Text] [Related]
20. Sickling-suppressive effects of chrysin may be associated with sequestration of deoxy-haemoglobin, 2,3-bisphosphoglycerate mutase, alteration of redox homeostasis and functional chemistry of sickle erythrocytes.
Muhammad A; Waziri AD; Forcados GE; Sanusi B; Sani H; Malami I; Abubakar IB; Muhammad A; Muhammad RA; Mohammed HA
Hum Exp Toxicol; 2020 Apr; 39(4):537-546. PubMed ID: 31876182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
